Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397027 | 0.85 | CYP1A2 (0.45) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL11017179 | 0.78 | CYP1A2 (0.80) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL30559673 | 0.77 | CCNA2 (0.46) | CYP1A2 | |
| SCHEMBL26977474 | 0.77 | CCNA2 (0.46) | CYP1A2 | |
| SCHEMBL21341669 | 0.77 | DHPS (0.40) | CYP1A2 | |
| SCHEMBL16796101 | 0.76 | CYP1A2 (0.53) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL1332904 | 0.76 | CYP1A2 (0.39) | CYP1A2ALDH1A1ALOX15TSHRCRHR1 | |
| SCHEMBL1397084 | 0.74 | CYP1A2 (0.38) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL24943849 | 0.74 | CYP1A2 (0.38) | CYP1A2ALDH1A1ALOX15TSHR | |
| SCHEMBL9432184 | 0.74 | CYP1A2 (0.61) | CYP1A2ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-118159533-A | Heterocyclic compounds and their use | 艾森医药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4370212-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-116478098-A | Polyimide precursor, polyimide, preparation method and application thereof | 深圳先进电子材料国际创新研究院 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | CYP1A2 1994/4885ALDH1A1 1877/4885ALOX15 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.